A 16 Week Randomized Controlled Trial of the Effect of Aripiprazole Versus Standard of Care on Rates of Non-HDL Cholesterol Among Schizophrenia and Bipolar Patients With Pre-Existing Metabolic Syndrome.

Trial Profile

A 16 Week Randomized Controlled Trial of the Effect of Aripiprazole Versus Standard of Care on Rates of Non-HDL Cholesterol Among Schizophrenia and Bipolar Patients With Pre-Existing Metabolic Syndrome.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2013

At a glance

  • Drugs Aripiprazole; Olanzapine; Quetiapine; Risperidone
  • Indications Bipolar I disorders; Schizoaffective disorder; Schizophrenia
  • Focus Pharmacodynamics
  • Acronyms OPT
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Nov 2013 Last checked against ClinicalTrials.gov record.
    • 21 Jun 2010 Actual patient number (28) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top